Oncotarget: Aggressive Breast Cancer Needs better Treatment
Oncotarget is a popular biomedical journal that is changing the lives of many people in the modern times. The journal is peer-reviewed, and it is published twice a week. Oncotarget specializes in all aspects of cancer. In the recent times, the journal has been covering subsections beyond cancer such as immunology, aging, microbiology, pathology, autophagy, and chromosomes. The institution has won the hearts of many people in the market for releasing accurate information.
Just recently, the journal published some information concerning breast cancer. According to Oncotarget, an aggressive breast cancer cell is believed to respond to a special hormone therapy if medical experts are able to express a protein called estrogen receptor. The medical researchers say that they are looking forward to developing drugs that will cure this form of breast cancer in a short time. Follow Oncotarget on Twitter.
According to Oncotarget, breast cancer cells have various types of hormone receptors. These particular cells play a crucial role in the function and growth of breast cancer cells. Fifteen percent of the total breast cancers have triple negative breast cancer. This disease is very aggressive in most cases, and it is defined by the absence of several receptor proteins. Without the receptors, the cancers become very resistant to the available hormone treatment that is given to breast cancer patients.
Although there have been several advancements in the medical department, experts have not yet introduced a real cure for cancer treatment. Most of the advanced treatment methods have not assisted the people living with TNBC. In most cases, the form of cancer will spread to other parts of the body. Oncotarget says that more research must be done so that experts can come up with a better kind of treatment for this aggressive cancer. Visit Oncotarget’s profile page at facebook.com
Mikhail Blagosklonny is an influential scientist who currently works with Oncotarget. The businessman has a lot of knowledge in cancer and aging, and he has done a lot to make Oncotarget the best in the market. The experienced businessman makes sure that all the medical research that is published by Oncotarget is factual so that the readers are not misled. Mikhail is the founder of the bi-weekly journal.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/